HIGHLIGHTS
- who: Angiolo Gadducci from the Papa Giovanni XXIII Hospital, Italy University of Turin, Italy have published the research work: Trabectedin and lurbinectedin: Mechanisms of action, clinical impact, and future perspectives in uterine and soft tissue sarcoma, ovarian carcinoma, and endometrial carcinoma, in the Journal: (JOURNAL)
- what: In the second randomized stage of the study, an objective response was noted in 17% of 30 patients treated with lurbinectedin versus 0% of the 29 treated with topotecan.
- future: Agents targeting TAMs and the other components of TME such as trabectedin and lurbinectedin can offer interesting . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.